Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1353550-13-6
2. Hm61713
3. Bi 1482694
4. 1802181-20-9
5. Olmutinib [inn]
6. Hm-61713
7. Olmutinib [who-dd]
8. Bi-1482694
9. N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide
10. Chl9b67l95
11. N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide
12. N-{3-[(2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}thieno[3,2-d]pyrimidin-4-yl)oxy]phenyl}prop-2-enamide
13. 2-propenamide, N-(3-((2-((4-(4-methyl-1-piperazinyl)phenyl)amino)thieno(3,2-d)pyrimidin-4-yl)oxy)phenyl)-
14. N-(3-((2-(4-(4-methylpiperazin-1-yl)anilino)thieno(3,2-d)pyrimidin-4-yl)oxy)phenyl)prop-2-enamide
15. 1938072-69-5
16. 2-propenamide, N-[3-[[2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]thieno[3,2-d]pyrimidin-4-yl]oxy]phenyl]-
17. Hm-61713 (bi-1482694)
18. Hm 61713
19. Hm71224;olmutinib
20. Olmutinib (usan/inn)
21. Olmutinib [usan:inn]
22. Olmutinib [usan]
23. Olmutinib(hm-71224)
24. Unii-chl9b67l95
25. Gtpl9196
26. Chembl3786343
27. Schembl14914931
28. Ex-a879
29. Dtxsid001319119
30. Bcp16733
31. Bdbm50160871
32. Mfcd29918158
33. Nsc792848
34. Nsc800980
35. S8294
36. Akos030632791
37. Zinc198970879
38. Ccg-269594
39. Cs-5413
40. Db13164
41. Nsc-792848
42. Nsc-800980
43. Sb19797
44. Example 1 [us20130116213]
45. Ac-30225
46. Ac-35418
47. As-74850
48. Hm 71224
49. Hy-19730
50. Bi1482694
51. Ds-015877
52. Ft-0700176
53. Olmutinib (hm61713, Bi 1482694)
54. J3.435.413h
55. D10859
56. W12116
57. Hm61713, Bi 1482694
58. A900418
59. J-690142
60. Q27088175
61. 4-{[4-({[(1r,2s)-2-phenylcyclopropyl]amino}methyl)-1-piperidinyl]methyl}benzoic Acid
62. Bi1482694;bi 1482694;bi-1482694;hm 61713;hm-61713;hm61713
63. N-(3-(2-(4-(4 Methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidine-4-yloxy)phenyl)acrylamide
64. N-(3-(2-(4-(4-methylpiperazin-1-yl)phenylamino)thieno[3,2-d]pyrimidine-4-yloxy)phenyl)acrylamide
65. N-(3-{2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thieno[3,2-d]pyrimidin-4-yloxy}-phenyl)-acrylamide
Molecular Weight | 486.6 g/mol |
---|---|
Molecular Formula | C26H26N6O2S |
XLogP3 | 4.7 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 7 |
Exact Mass | 486.18379527 g/mol |
Monoisotopic Mass | 486.18379527 g/mol |
Topological Polar Surface Area | 111 Ų |
Heavy Atom Count | 35 |
Formal Charge | 0 |
Complexity | 712 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
For use in treatment of metastatic T790M mutation positive non-small cell lung cancer.
Olmutinib selectively and irreversibly binds and inhibits epidermal growth factor receptors (EGFR) with the T790M activating mutation. EGFRs are frequently over-expressed in lung cancer and contribute to activation of the phosphoinositide 3-kinase and mitogen activated protein kinase pathways which both promote cell survival and proliferation. By inhibiting EGFR activation, olmutinib attenuates the activation of these tumor promoting pathways.
L - Antineoplastic and immunomodulating agents
L01 - Antineoplastic agents
L01E - Protein kinase inhibitors
L01EB - Epidermal growth factor receptor (egfr) tyrosine kinase inhibitors
L01EB06 - Olmutinib
Absorption
tmax of 3-4h with oral administration.
Route of Elimination
Data not yet available.
Volume of Distribution
Data not yet available.
Clearance
Data not yet available.
Data not yet available.
8-11h.
Olmutinib covalently binds a cysteine residue near the kinase domain of mutant EGFRs to prevent phosphorylation of the receptor. This inhibits receptor signalling as phosphorylation is necessary for recruitment of signalling cascade proteins.
ABOUT THIS PAGE
17
PharmaCompass offers a list of Olmutinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Olmutinib manufacturer or Olmutinib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Olmutinib manufacturer or Olmutinib supplier.
PharmaCompass also assists you with knowing the Olmutinib API Price utilized in the formulation of products. Olmutinib API Price is not always fixed or binding as the Olmutinib Price is obtained through a variety of data sources. The Olmutinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Olmutinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Olmutinib, including repackagers and relabelers. The FDA regulates Olmutinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Olmutinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Olmutinib supplier is an individual or a company that provides Olmutinib active pharmaceutical ingredient (API) or Olmutinib finished formulations upon request. The Olmutinib suppliers may include Olmutinib API manufacturers, exporters, distributors and traders.
click here to find a list of Olmutinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Olmutinib Drug Master File in Korea (Olmutinib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Olmutinib. The MFDS reviews the Olmutinib KDMF as part of the drug registration process and uses the information provided in the Olmutinib KDMF to evaluate the safety and efficacy of the drug.
After submitting a Olmutinib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Olmutinib API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Olmutinib suppliers with KDMF on PharmaCompass.
Olmutinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Olmutinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Olmutinib GMP manufacturer or Olmutinib GMP API supplier for your needs.
A Olmutinib CoA (Certificate of Analysis) is a formal document that attests to Olmutinib's compliance with Olmutinib specifications and serves as a tool for batch-level quality control.
Olmutinib CoA mostly includes findings from lab analyses of a specific batch. For each Olmutinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Olmutinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Olmutinib EP), Olmutinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Olmutinib USP).